-1.png)
In recent years, the landscape of cannabis accessibility has dramatically shifted, not just in conventional dispensaries but in everyday storefronts across the United States. This new wave of products, stemming from the 2018 Farm Bill's legal distinction between hemp and marijuana, has ushered in an era of synthetic cannabinoids like Delta-8 THC, Delta-10 THC, and THCA, which are finding their way into the hands of consumers and, inevitably, into emergency departments. As emergency clinicians, it's crucial to understand the implications of these substances, their legal ambiguities, and their effects on public health.
The Legal Landscape
Traditionally, cannabis is categorized into hemp and marijuana based on the concentration of Delta-9 THC, the primary psychoactive component. Hemp, with less than 0.3% Delta-9 THC, has been deemed non-psychoactive and thus federally legal. However, this definition overlooked the multitude of other cannabinoids present in the cannabis plant, which can be psychoactive when isolated and concentrated, leading to the current proliferation of synthetic cannabinoid products.
The Farm Bill and Synthetic Cannabinoids
The 2018 Farm Bill was a turning point, removing hemp from the controlled substances list and inadvertently opening the floodgates for synthetic cannabinoids. Retailers, leveraging the legal loophole that only Delta-9 THC is regulated, began selling products laced with Delta-8 THC, Delta-10 THC, and, more recently, THCA. These substances, while chemically distinct from Delta-9 THC by mere molecular differences, offer similar psychoactive effects when concentrated and consumed, blurring the lines of legality and safety.
Emergency Department Visits
The rise of these synthetic cannabinoids has led to a surge in emergency department visits. Patients often present with symptoms indistinguishable from traditional marijuana intoxication, unaware of the potency and potential risks of these legal alternatives. The misconception that legality equates to safety has led to dangerous experimentation, with individuals consuming high doses without understanding the implications.
The Unregulated Market
One of the most significant challenges posed by synthetic cannabinoids is the lack of regulation. Products sold in gas stations, CBD stores, vapor shops, liquor stores and even online can vary widely in composition, potency, and purity. The process of chemically extracting and concentrating cannabinoids like Delta-8 THC often involves solvents and other chemicals that may remain in the final product, posing additional health risks when consumed.
Recommendations for Clinicians
As front-line responders to the consequences of synthetic cannabinoid use, we must be well-informed and vigilant. It is critical to approach cases of synthetic cannabinoid intoxication with the same level of urgency as traditional marijuana or other psychoactive substances. Educating patients about these substances’ risks, potency, and unpredictable nature is vital, underscoring that legality does not necessarily imply safety. With the upcoming renewal of the Farm Bill, it is essential for clinicians to stay informed about changes in the regulation and legal status of hemp and synthetic cannabinoids to better understand the evolving landscape and its implications for patient care.
Read more about the conversion of CBD into THC here.
